Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

This two-part study is first looking at whether certain solid tumors (colorectal, lung, pancreatic, and others) have a specific genetic change called HLA loss of heterozygosity (LOH) — where cancer cells hide from the immune system. In the second part, researchers will collect blood cells (via a process called apheresis) from eligible patients to manufacture CAR T-cell therapies that can specifically target those tumors. **You may be eligible if...** - You have been diagnosed with an advanced solid tumor (colorectal, lung, pancreatic, mesothelioma, or ovarian cancer) - In Part 2: Your tumor has a specific genetic pattern (HLA-A*02 heterozygous with HLA LOH confirmed by genetic testing) - Your cancer has spread or cannot be removed surgically - You are in good health overall (ECOG 0–1 for Part 2) **You may NOT be eligible if...** - You have had a bone marrow or solid organ transplant - You have had another cancer in the past 5 years (with some exceptions like early-stage skin cancer) Talk to your doctor to see if this trial is right for you.